The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy

類似資料

• AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice
  著者:: Crudele, Julie M., 等
  出版事項: (2015)
• Complete correction of hemophilia B phenotype by FIX-Padua skeletal muscle gene therapy in an inhibitor-prone dog model
  著者:: French, Robert A., 等
  出版事項: (2018)
• Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity
  著者:: Samelson-Jones, Benjamin J., 等
  出版事項: (2019)
• Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model
  著者:: Arruda, Valder R., 等
  出版事項: (2005)
• Safety of AAV Factor IX Peripheral Transvenular Gene Delivery to Muscle in Hemophilia B Dogs
  著者:: Haurigot, Virginia, 等
  出版事項: (2010)